www.fdanews.com/articles/152676-exelixis-announces-cometriq-is-now-available-in-the-u-s

Exelixis Announces Cometriq Is Now Available in the U.S.

January 25, 2013

Exelixis announced the commercial availability of Cometriq (cabozantinib) for the treatment of patients with progressive, metastatic medullary thyroid cancer.
Businesswire